Navigation Links
Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
Date:6/23/2009

LAUSANNE, Switzerland, June 23 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that Salvacyl(R) (also known under the trade names Moapar(R) and Salvapar(R)), was launched in Germany in May 2009, by Dr R. Pfleger GmbH. In April 2009, Salvacyl(R) was also launched on a preliminary basis in Belgium. The effective commercial launch will take place in a couple of months. Salvacyl(R) contains the active substance triptorelin, a gonadotropin releasing hormone (GnRH) agonist analogue. The product will be prescribed for the reversible reduction of serum testosterone to the level of castration in order to lower sexual drive in adult men suffering from sexual deviations.

"This is a great accomplishment for Debiopharm. Salvacyl(R) is the fourth product we have developed and made available to doctors for the treatment of a serious condition," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We can now offer people suffering from this controversial disorder an alternative and a complementary treatment to surgical and currently used chemical castrations, as well as to other types of medication."

Salvacyl(R) is registered in seven other European countries, including France, the United Kingdom, Sweden, Norway, Denmark, the Netherlands and Finland, and will be launched progressively by Debiopharm's commercial partners in the course of 2009 and 2010. Moapar(R) is currently undergoing a registration procedure with Swissmedic in Switzerland.

About Salvacyl(R)

In the treatment of sexual deviations in men, intra-muscular administration of Salvacyl(R) every 3 months, in combination with psychotherapy, is an advantage over daily oral forms or intra-muscular weekly injections that are required with anti-androgens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA). There are also fewer side effects.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

    Debiopharm S.A. Contacts
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com

    Additional Media Contacts
    In London
    Maitland
    Brian Hudspith
    Tel: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com



'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
5. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
6. More Than 300 New Medicines Being Developed for Mental Illnesses
7. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
8. Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists
9. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
10. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
11. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):